Use of Economic Evaluation in Decision Making Evidence and Recommendations for Improvement

被引:5
|
作者
Simoens, Steven [1 ]
机构
[1] Katholieke Univ Leuven, Res Ctr Pharmaceut Care & Pharmacoecon, B-3000 Louvain, Belgium
关键词
HEALTH TECHNOLOGY-ASSESSMENT; COST-EFFECTIVENESS; CLINICAL-EXCELLENCE; PHARMACEUTICAL CARE; NATIONAL-INSTITUTE; TASK-FORCE; INFORMATION; EUROPE; GROWTH; NICE;
D O I
10.2165/11538120-000000000-00000
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Information about the value for money of a medicine as derived from an economic evaluation can be used for decision-making purposes by policy makers, healthcare payers, healthcare professionals and pharmaceutical companies. This article illustrates the use of economic evaluation by decision makers and formulates a number of recommendations to enhance the use of such evaluations for decision-making purposes. Over the last decades, there has been a substantial increase in the number of economic evaluations assessing the value for money of medicines. Economic evaluation is used by policy makers and healthcare payers to inform medicine pricing/reimbursement decisions in more and more countries. It is a suitable tool to evaluate medicines and to present information about their value for money to decision makers in a familiar format. In order to fully exploit the use of economic evaluation for decision-making purposes, researchers need to take care to conduct such economic evaluations according to methodologically sound principles. Additionally, researchers need to take into account the decision-making context. They need to identify the various objectives that decision makers pursue and discuss how decision makers can use study findings to attain these objectives. These issues require further attention from researchers, policy makers, healthcare payers, healthcare professionals and pharmaceutical companies with a view to optimizing the use of economic evaluation in decision making.
引用
收藏
页码:1917 / 1926
页数:10
相关论文
共 50 条
  • [1] Using Economic Evaluation in Policy Decision-Making in Asian Countries: Mission Impossible or Mission Probable?
    Yothasamut, Jomkwan
    Tantivess, Sripen
    Teerawattananon, Yot
    VALUE IN HEALTH, 2009, 12 : S26 - S30
  • [2] The use of pharmacoeconomic evidence to support formulary decision making in Saudi Arabia: Methodological recommendations
    AL Aqeel, Sinaa A.
    Al-Sultan, Mohammed
    SAUDI PHARMACEUTICAL JOURNAL, 2012, 20 (03) : 187 - 194
  • [3] Economic Evaluation and Decision Making in the UK
    Martin J. Buxton
    PharmacoEconomics, 2006, 24 : 1133 - 1142
  • [4] Role of economic evidence in coverage decision-making in South Korea
    Bae, Eun-Young
    Kim, Hui Jeong
    Lee, Hye-Jae
    Jang, Junho
    Lee, Seung Min
    Jung, Yunkyung
    Yoon, Nari
    Kim, Tae Kyung
    Kim, Kookhee
    Yang, Bong-Min
    PLOS ONE, 2018, 13 (10):
  • [5] EVIDENCE INFORMED DECISION MAKING: THE USE OF "COLLOQUIAL EVIDENCE" AT NICE
    Sharma, Tarang
    Choudhury, Moni
    Kaur, Bindweep
    Naidoo, Bhash
    Garner, Sarah
    Littlejohns, Peter
    Staniszewska, Sophie
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2015, 31 (03) : 138 - 146
  • [6] Use of evidence in economic decision models: Practical issues and methodological challenges
    Cooper, N. J.
    Sutton, A. J.
    Ades, A. E.
    Paisley, S.
    Jones, D. R.
    HEALTH ECONOMICS, 2007, 16 (12) : 1277 - 1286
  • [7] Challenges to decision-making processes in the national HTA agency in Brazil: operational procedures, evidence use and recommendations
    Tania Yuka Yuba
    Hillegonda Maria Dutilh Novaes
    Patrícia Coelho de Soárez
    Health Research Policy and Systems, 16
  • [8] Challenges to decision-making processes in the national HTA agency in Brazil: operational procedures, evidence use and recommendations
    Yuba, Tania Yuka
    Dutilh Novaes, Hillegonda Maria
    de Soarez, Patricia Coelho
    HEALTH RESEARCH POLICY AND SYSTEMS, 2018, 16
  • [9] Understanding the impact of economic evidence on clinical decision making: A discrete choice experiment in cardiology
    Torbica, Aleksandra
    Fattore, Giovanni
    SOCIAL SCIENCE & MEDICINE, 2010, 70 (10) : 1536 - 1543
  • [10] New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations
    Shiroiwa, Takeru
    Fukuda, Takashi
    Ikeda, Shuriya
    Takura, Tomoyuki
    HEALTH POLICY, 2017, 121 (08) : 836 - 841